Search

Your search keyword '"Gehrig, A."' showing total 628 results
Start Over Author "Gehrig, A." Journal gynecologic oncology
628 results on '"Gehrig, A."'

1. Radical hysterectomy case volume and cervical cancer treatment in the era of COVID-19: A multi-site analysis of National Cancer Institute-designated Comprehensive Cancer Centers

Author

Wickenheisser, Natalie E., Dillon, Mairead, Broadwater, Gloria, Zacherl, Kathleen, Bixel, Kristin, Levine, Monica, Newton, Meredith, Thel, Hannah, Tucker, Katherine, Gehrig, Paola, Khetan, Varun U., Brunette-Masi, Laurie L., Matsuo, Koji, Khouri, Olivia R., Duhon, Ashley, Gowthaman, Divya, Cowan, Matthew, Mojdehbakhsh, Rachel, Rose, Stephen, Olawaiye, Alexander, Davidson, Brittany A., Moss, Haley A., and Havrilesky, Laura J.

Published
2023
Full Text
View/download PDF

9. Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?

Author

Beavis, Anna L., Yen, Ting-Tai, Stone, Rebecca L., Wethington, Stephanie L., Carr, Caitlin, Son, Ji, Chambers, Laura, Michener, Chad M., Ricci, Stephanie, Burkett, Wesley C., Richardson, Debra L., Staley, Allison-Stuart, Ahn, Susie, Gehrig, Paola A., Torres, Diogo, Dowdy, Sean C., Sullivan, Mackenzie W., Modesitt, Susan C., Watson, Catherine, Veade, Ashely, Ehrisman, Jessie, Havrilesky, Laura, Secord, Angeles Alvarez, Loreen, Amy, Griffin, Kaitlyn, Jackson, Amanda, Viswanathan, Akila N., Jager, Leah R., and Fader, Amanda N.

Published
2020
Full Text
View/download PDF

14. Clinical calculator redefines prognosis for high-risk early-stage ovarian cancers and potential to guide treatment in the adjuvant setting

Author

Anthony, Bui, Paola A, Gehrig, Sharad, Ghamande, Bunja J, Rungruang, John K, Chan, and David P, Mysona

Subjects
Oncology, Obstetrics and Gynecology
Abstract

To determine the utility of a clinical calculator to redefine prognosis and need for chemotherapy among patients with early-stage high-risk epithelial ovarian cancer.Data were abstracted for stage I-II, high-risk ovarian cancer from the National Cancer Database from years 2005 to 2015. Based on demographic, pathologic, surgical, and laboratory characteristics, a clinical score was developed using Cox regression. Propensity score weighting was used to adjust for differences between patients who did and did not receive chemotherapy.Of 8188 patients with early-stage high-risk ovarian cancer, 6915 (84%) did and 1273 (16%) did not receive chemotherapy. A clinical calculator was created utilizing age, stage, histology, grade, tumor size, number of pelvic and paraaortic lymph nodes examined, the presence of malignant ascites, and CA125. The calculator divided patients into low, moderate, and high-risk groups with 5-year OS (overall survival) of 92%, 82%, and 66%, and 10-year OS of 85%, 67%, and 44%, respectively. Chemotherapy improved 5-year OS and 10-year OS in the high-risk group (56% to 73%; p0.001, 34% to 48%; p0.001). The moderate risk group had improved 5-year OS (80% to 85%; p = 0.01) but not 10-year OS (66% to 66%; p = 0.13). Chemotherapy did not improve 5-year or 10-year OS in low-risk patients (93% to 92%, p = 1.0, 86% to 84%, p = 0.99).The prognosis among high-risk early-stage ovarian cancer patients is heterogeneous. This calculator may aid in patient-centered counseling regarding potential treatment benefits.

Published
2022

30. Genomic alterations, molecularly targeted therapy and race: Real world data from the Endometrial Cancer Molecularly Targeted Therapy Consortium (LBA 8)

Author

Secord, Angeles Alvarez, primary, Pothuri, Bhavana, additional, Backes, Floor, additional, Thaker, Premal, additional, Gehrig, Paola, additional, Previs, Rebecca, additional, Borden, Lindsay, additional, Thomas, Samantha, additional, Jackson, Amanda, additional, Konecny, Gottfried, additional, Duska, Linda, additional, Arend, Rebecca, additional, Wright, Jason, additional, Corr, Bradley, additional, Maxwell, G. Larry, additional, Cosgrove, Casey, additional, Mullen, Mary, additional, Moore, Kathleen, additional, Herzog, Thomas, additional, Cohen, Joshua, additional, Gockley, Allison, additional, Gaillard, Stephanie, additional, Fader, Amanda, additional, Berchuck, Andrew, additional, and Bae-Jump, Victoria, additional

Published
2022
Full Text
View/download PDF

40. Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations

Author

Floor J. Backes, Pamela T. Soliman, Renata R. Urban, W.M. Burke, J. Spencer Thompson, Rebecca C. Arend, Bhavana Pothuri, Paola A. Gehrig, and Chad A. Hamilton

Subjects
0301 basic medicine, medicine.medical_specialty, Gynecologic oncology, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Survivorship curve, medicine, Adjuvant therapy, Humans, Fertility preservation, Evidence-Based Medicine, Molecular pathology, business.industry, General surgery, Endometrial cancer, Obstetrics and Gynecology, medicine.disease, Evidence based review, Endometrial Neoplasms, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, Presentation (obstetrics), business
Abstract

In 2014, the Society of Gynecologic Oncology's Clinical Practice Committee published a clinical update reviewing the treatment of women with endometrial cancer. At that time, there had been significant advances in the diagnosis, work-up, surgical management, and available treatment options allowing for more optimal care of affected women. Despite these advances, the incidence of endometrial cancer as well as the deaths attributable to the disease have continued to rise; from 1987 to 2014 there has been a 75% increase in cases and almost 300% increase in endometrial cancer deaths. Fortunately, since then, there has been progress in the treatment of patients with endometrial cancer with increased utilization of molecular pathology, greater understanding of genetic predisposition, enhanced methods for lymph node assessment, a broader understanding of the efficacy of radiation and chemotherapy, and a more efficient approach to survivorship and surveillance. The purpose of this document is to present a comprehensive review of this progress.The authors reviewed the available evidence, contributed to the development of this manuscript, provided critical review of the guidelines, and finalized the manuscript recommendations. The review was also presented to and approved by the Society of Gynecologic Oncology (SGO) Clinical Practice Committee, SGO Publications Committee, and the SGO board members prior to submission for publication. The recommendations for this manuscript were developed by a panel of gynecologic oncologists who were members of the SGO Clinical Practice and Education Committees. Panelists reviewed and considered evidence from current uterine cancer literature. The terminology used in these guidelines was adopted from the ASCCP management guidelines [1] using a two-part rating system to grade the strength of recommendation and quality of evidence (Table 1). The rating for each recommendation is given in parentheses.

Published
2021

41. Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II

Author

Chad A. Hamilton, Bhavana Pothuri, Rebecca C. Arend, Floor J. Backes, Paola A. Gehrig, Pamela T. Soliman, J. Spencer Thompson, Renata R. Urban, and William M. Burke

Subjects
Evidence-Based Medicine, Oncology, Humans, Obstetrics and Gynecology, Female, Endometrial Neoplasms
Abstract

In 2014, the Society of Gynecologic Oncology's Clinical Practice Committee published a clinical update reviewing the treatment of women with endometrial cancer. At that time, there had been significant advances in the diagnosis, work-up, surgical management, and available treatment options allowing for more optimal care of affected women. This manuscript, Part II in a two-part series, includes specific recommendations on treatment of recurrent disease, post treatment surveillance and survivorship, considerations for younger women, and special situations. Part I covered histopathology and molecular pathology, risk factors, presentation and diagnostic approach, surgical approach and adjuvant therapy.

Published
2021

42. Accuracy of preoperative cross-sectional imaging in cervical cancer patients undergoing primary radical surgery

Author

S. Allison Staley, Leslie H. Clark, Katherine R. Tucker, and Paola A. Gehrig

Subjects
Adult, 0301 basic medicine, medicine.medical_specialty, Uterine Cervical Neoplasms, Cervix Uteri, Hysterectomy, Surgical pathology, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Positron Emission Tomography Computed Tomography, Preoperative Care, medicine, Humans, False Positive Reactions, Radical surgery, Radical Hysterectomy, False Negative Reactions, Aged, Neoplasm Staging, Retrospective Studies, Cervical cancer, Sentinel Lymph Node Biopsy, business.industry, Medical record, nutritional and metabolic diseases, Obstetrics and Gynecology, Retrospective cohort study, Middle Aged, medicine.disease, Magnetic Resonance Imaging, 030104 developmental biology, Oncology, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Conventional PCI, Feasibility Studies, Lymph Node Excision, Female, Radiology, False positive rate, Sentinel Lymph Node, Tomography, X-Ray Computed, business
Abstract

Objective We aim to describe the false negative (FN) and false positive (FP) rates of preoperative cross-sectional imaging (PCI) prior to radical surgery for cervical cancer. Methods A retrospective cohort study of patients who underwent radical hysterectomy for early-stage cervical cancer from January 2010 until December 2017 at a single tertiary care center was performed. Patients were included if they underwent preoperative PCI and radical surgery. Patient demographics and clinicopathologic information were recorded from medical record review. Descriptive statistics were used. Results Overall, 106 patients met inclusion criteria. Eighty-four percent (89/106) of patients had no suspicion for metastatic disease on PCI, while 16% (17/106) had suspicion for metastatic disease. Of the 89 without suspicion for metastatic disease on PCI, 16% (14/89) had a false negative study with metastatic disease identified on final surgical pathology. False negative rates by modality were 16% (11/70) for PET/CT and 6% (2/33) for diagnostic CT. Of the 17 cases with suspicion for metastatic disease on imaging, 53% (9/17) were false positive studies with no metastatic disease identified histologically. False positive rates by modality were 7% (5/70) for PET/CT and 12% (4/33) for diagnostic CT. Conclusion PCI is a tool to help identify patients who are optimal candidates for radical surgery. In this sample, the false negative rate was 16%, and false positive rate was 53% for PCI among women who underwent primary radical surgery. Further study is needed to explore preoperative testing that may more accurately identify optimal surgical candidates.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results